Key result
Compound 21 lowers blood glucose and enhances islet-cell function in rats and human progenitor cells.
Compound 21, an AT2 receptor agonist, demonstrates beneficial effects on islet cell function and regeneration in preclinical models, suggesting potential therapeutic value for diabetes.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for AT2 agonism in beta-cell regeneration; clinical trials required before any therapeutic consideration in diabetes.
OBJECTIVES: We investigated the effects of compound 21 (C21), a nonpeptide angiotensin II type 2 receptor agonist, on islet cell function and survival in streptozotocin (STZ)-treated neonatal rats and human pancreatic progenitor cells. METHODS: Neonatal rats were randomized into 5 groups, including a control, an STZ (100 mg/kg, intraperitoneally), and 3 STZ + C21 (0.25, 0.5, and 1 mg/kg per day for 7 days, intraperitoneally) groups. Body weight and blood glucose were monitored daily. On the last experimental day, serum insulin levels and glucose tolerance were assessed, and the rat pups' pancreata were extracted for examination of islet cell function/mass and involvement of signaling pathways. RESULTS: The C21-treated STZ rats, particularly in the 0.5- and 1 mg/kg-dosage groups, had significantly decreased blood glucose, increased serum insulin concentrations, higher glucose-stimulated insulin secretion activity, and greater islet-cell mass and up-regulated expression of insulin and Ngn3 in the pancreas than did the control groups; these rats also demonstrated increased β-cell proliferation, lower superoxide levels and enhanced SOD1 expression, and up-regulated phospho-AKT expression; consistently, similar results were also observed in human pancreatic progenitor cells. CONCLUSIONS: These data suggest that C21 has a beneficial effect on islet cell function and regeneration, probably via proliferative and antioxidative pathways.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) studied Streptozotocin-induced islet dysfunction. Compound 21 (C21) vs. Control and STZ alone was evaluated on Blood glucose, serum insulin concentrations, glucose-stimulated insulin secretion, and islet-cell mass. Compound 21 significantly decreased blood glucose, increased serum insulin, and enhanced islet-cell mass and function in streptozotocin-treated neonatal rats and human pancreatic progenitor cells.
Synapse has enriched 10 related papers. Consider them for comparative context: